SEC Filing · 6-K
RedHill Biopharma Ltd.
SEC Filing
Press release in this filing
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results →Company context
We are a specialty biopharmaceutical company, primarily focused on GI, infectious diseases and oncology. Our primary goal is to become a leading specialty biopharmaceutical company.
Current securities
As-filed source
As filedOpen full document ↗